Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ACXPNASDAQ:AGLENASDAQ:ENOBNASDAQ:IMPL On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeACXPAcurx Pharmaceuticals$0.55-23.6%$0.40$0.30▼$3.33$12.92M-1.381.62 million shs3.54 million shsAGLEAeglea BioTherapeutics$11.47$2.66▼$32.75$48.64M2.5795,409 shs43,300 shsENOBEnochian Biosciences$0.61$0.39▼$2.99$40.80M1.09137,347 shs88,300 shsIMPLImpel Pharmaceuticals$0.27$0.02▼$4.20$956K1.17682,655 shs720,000 shs20 High-Yield Dividend Stocks that Could Ruin Your RetirementAlmost everyone loves strong dividend-paying stocks, but high yields can signal danger. Discover 20 high-yield dividend stocks paying an unsustainably large percentage of their earnings. Enter your email to get this report and avoid a high-yield dividend trap.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceACXPAcurx Pharmaceuticals0.00%+80.33%+38.12%+29.90%-75.56%AGLEAeglea BioTherapeutics0.00%0.00%0.00%0.00%0.00%ENOBEnochian Biosciences0.00%0.00%0.00%0.00%0.00%IMPLImpel Pharmaceuticals0.00%0.00%0.00%0.00%0.00%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationACXPAcurx Pharmaceuticals2.7941 of 5 stars3.55.00.00.02.11.70.0AGLEAeglea BioTherapeuticsN/AN/AN/AN/AN/AN/AN/AN/AENOBEnochian BiosciencesN/AN/AN/AN/AN/AN/AN/AN/AIMPLImpel PharmaceuticalsN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceACXPAcurx Pharmaceuticals 3.00Buy$8.001,354.55% UpsideAGLEAeglea BioTherapeutics 0.00N/AN/AN/AENOBEnochian Biosciences 0.00N/AN/AN/AIMPLImpel Pharmaceuticals 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest ACXP, IMPL, AGLE, and ENOB Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/15/2025ACXPAcurx PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy$8.00(Data available from 6/22/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookACXPAcurx PharmaceuticalsN/AN/AN/AN/A$0.03 per shareN/AAGLEAeglea BioTherapeutics$2.33M0.00N/AN/A($60.61) per share0.00ENOBEnochian BiosciencesN/AN/AN/AN/A$1.37 per shareN/AIMPLImpel Pharmaceuticals$20.99M0.00N/AN/A($1.86) per share0.00Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateACXPAcurx Pharmaceuticals-$14.10M-$0.70N/AN/AN/AN/A-526.78%-223.78%8/8/2025 (Estimated)AGLEAeglea BioTherapeutics-$83.82M-$75.59N/AN/AN/A-22,195.36%-132.05%-146.87%N/AENOBEnochian Biosciences-$113.43MN/A0.00N/AN/AN/A-154.69%-130.66%N/AIMPLImpel Pharmaceuticals-$106.31M-$3.13N/AN/AN/A-353.93%N/A-127.43%N/ALatest ACXP, IMPL, AGLE, and ENOB EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/12/2025Q1 2025ACXPAcurx Pharmaceuticals-$0.14-$0.11+$0.03-$0.11N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthACXPAcurx PharmaceuticalsN/AN/AN/AN/AN/AAGLEAeglea BioTherapeuticsN/AN/AN/AN/AN/AENOBEnochian BiosciencesN/AN/AN/AN/AN/AIMPLImpel PharmaceuticalsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioACXPAcurx PharmaceuticalsN/A1.931.93AGLEAeglea BioTherapeuticsN/A4.594.59ENOBEnochian BiosciencesN/A0.330.33IMPLImpel PharmaceuticalsN/A0.190.13Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipACXPAcurx Pharmaceuticals11.53%AGLEAeglea BioTherapeuticsN/AENOBEnochian Biosciences7.16%IMPLImpel Pharmaceuticals73.88%Insider OwnershipCompanyInsider OwnershipACXPAcurx Pharmaceuticals26.00%AGLEAeglea BioTherapeutics6.60%ENOBEnochian Biosciences21.72%IMPLImpel Pharmaceuticals6.20%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableACXPAcurx Pharmaceuticals323.48 million17.38 millionOptionableAGLEAeglea BioTherapeutics694.05 million3.78 millionOptionableENOBEnochian Biosciences2258.28 million45.63 millionNot OptionableIMPLImpel Pharmaceuticals16023.90 million22.42 millionNot OptionableACXP, IMPL, AGLE, and ENOB HeadlinesRecent News About These CompaniesImpel-Stelda Enters Primary Packaging Business of Tube FillingOctober 12, 2024 | msn.comImpel gears up for growth with additions to leadership teamAugust 6, 2024 | autoremarketing.comImexpharm achieves net revenue of US$39.74 million in 2024H1July 26, 2024 | msn.comCompliant Marketing In The Pharmaceutical Industry's Regulatory MazeMay 17, 2024 | forbes.comImpel Pharmaceuticals Inc. (IMPLQ)March 13, 2024 | finance.yahoo.comImpel Pharma Mulls Sale, Signs Stalking Horse Deal; Files For Chapter 11 ProtectionDecember 20, 2023 | markets.businessinsider.comImpel Pharmaceuticals Announces Filing of Voluntary Chapter 11 Cases and Signing of "Stalking Horse" Agreement to Facilitate SaleDecember 20, 2023 | finance.yahoo.comImpel Pharma (NASDAQ: IMPL) up 140%, down again 22% - Welcome to Meme WorldNovember 23, 2023 | dhakatribune.comAdrian Adams steps down as CEO of Seattle's Impel PharmaceuticalsNovember 6, 2023 | bizjournals.comAnalysts Offer Insights on Healthcare Companies: Impel Pharmaceuticals (IMPL) and Relay Therapeutics (RLAY)October 9, 2023 | markets.businessinsider.comImpel Pharmaceuticals Announces Exploration of Strategic AlternativesOctober 5, 2023 | finance.yahoo.comImpel Pharmaceuticals (IMPL) Receives a Hold from JonesTradingSeptember 14, 2023 | markets.businessinsider.comUnderstanding the Risks of Investing in Impel Pharmaceuticals Inc. (IMPL)September 13, 2023 | knoxdaily.comWhy Is Impel Pharmaceuticals (IMPL) Stock Up 32% Today?September 8, 2023 | msn.comJonesTrading Reaffirms Their Hold Rating on Impel Pharmaceuticals (IMPL)August 22, 2023 | markets.businessinsider.comImpel Pharma Shares Tumble 46% After Breaching Terms of Credit AgreementAugust 16, 2023 | marketwatch.comImpel Pharma (NASDAQ:IMPL) Plummets on Viability ConcernsAugust 16, 2023 | msn.comWhy Is Impel Pharmaceuticals (IMPL) Stock Down 35% Today?August 16, 2023 | investorplace.comIMPL short interest jump by 35.22%, reflecting negative sentimentJuly 7, 2023 | knoxdaily.comBiotech Catches Major Premarket BidJuly 5, 2023 | theglobeandmail.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All Headlines3 Defense Stocks That Will Profit From a Golden DomeBy Chris Markoch | May 30, 2025View 3 Defense Stocks That Will Profit From a Golden DomeIPO Momentum Returns: 3 Stocks Rising After CoreWeave’s SurgeBy Dan Schmidt | June 20, 2025View IPO Momentum Returns: 3 Stocks Rising After CoreWeave’s SurgeWorkday Stock Price Implosion: An Automatic Buy for AI InvestorsBy Thomas Hughes | May 26, 2025View Workday Stock Price Implosion: An Automatic Buy for AI InvestorsAnalysts Are Bullish on Marvell Stock Despite Amazon Deal ConcernBy Leo Miller | June 2, 2025View Analysts Are Bullish on Marvell Stock Despite Amazon Deal ConcernAre NVIDIA's Ethernet Wins Signs of Hope or Horror for Arista?By Leo Miller | June 6, 2025View Are NVIDIA's Ethernet Wins Signs of Hope or Horror for Arista?ACXP, IMPL, AGLE, and ENOB Company DescriptionsAcurx Pharmaceuticals NASDAQ:ACXP$0.55 -0.17 (-23.61%) Closing price 06/20/2025 04:00 PM EasternExtended Trading$0.60 +0.04 (+8.18%) As of 06/20/2025 08:00 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Acurx Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops antibiotics to treat bacterial infections. The company's lead antibiotic candidate is ibezapolstat, a novel mechanism of action that targets the polymerase IIIC enzyme that is in Phase 2b clinical trial to treat patients with clostridium difficile infections. It also develops ACX-375C, a potential oral and parenteral treatment targeting gram-positive bacteria, including methicillin-resistant staphylococcus aureus, vancomycin-resistant enterococcus, and penicillin-resistant streptococcus pneumonia. Acurx Pharmaceuticals, Inc. was incorporated in 2017 and is headquartered in Staten Island, New York.Aeglea BioTherapeutics NASDAQ:AGLEAeglea BioTherapeutics, Inc., a clinical-stage biotechnology company, designs and develops human enzyme therapeutics for the treatment of rare metabolic diseases. The company's therapeutic candidates include pegtarviliase, a polyethylene glycol modified, which is in Phase I/II clinical trial for the treatment of patient with homocystinuria; and pegzilarginase, a recombinant human Arginase 1 that is in Phase III PEACE trial to evaluate the safety and efficacy for the treatment of Arginase 1 deficiency. In addition, its preclinical pipeline includes AGLE-325 for the treatment of cystinuria, as well as other research programs. The company was formerly known as Aeglea BioTherapeutics Holdings, LLC and changed its name to Aeglea BioTherapeutics, Inc. in March 2015. Aeglea BioTherapeutics, Inc. was founded in 2013 and is headquartered in Austin, Texas.Enochian Biosciences NASDAQ:ENOBEnochian Biosciences, Inc., a pre-clinical stage biotechnology company, engages in the research and development of pharmaceutical and biological products for the human treatment of human immunodeficiency virus (HIV), hepatitis B virus (HBV), and cancer. The company's product pipeline includes ENOB-HV-01 for autologous HIV curative treatment; ENOB-HV-12, a therapeutic HIV vaccine; and ENOB-HB-01, a gene therapy curative treatment for HBV. It develops ENOB-DC-11, an allogeneic dendritic cell therapeutic vaccine for solid tumors; ENOB-DC-12-XX, allogeneic dendritic cell therapeutic vaccine for other solid tumors; and ENOB-HV-21 for treating HIV with allogeneic natural killer (NK) and gamma delta T-cells. Enochian Biosciences, Inc. has strategic partnerships with the University of California, Fred Hutchinson Cancer Research Center, and Caring Cross. The company was incorporated in 2017 and is headquartered in Los Angeles, California.Impel Pharmaceuticals NASDAQ:IMPLImpel Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapies for patients suffering from central nervous system disease in the United States. Its lead product candidate is Trudhesa, an upper nasal formulation of dihydroergotamine for the acute treatment of migraine. Impel Pharmaceuticals Inc. was formerly known as Impel NeuroPharma, Inc. and changed its name to Impel Pharmaceuticals Inc. in April 2022. The company was incorporated in 2008 and is headquartered in Seattle, Washington. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas New All-Time Highs Coming for Broadcom? Wall Street Says Yes Smith & Wesson Stock Falls on Earnings Miss, Tariff Woes Marvell's New AI Chip Deals Capture Wall Street’s Attention Super Micro Computer Stock's Rally Backed by Strong Financials Forget the Fed: Home Depot Is the Real Gauge of the U.S. Consumer GE Aerospace Turns Engines Into Long-Term Profits 3 Reasons AMD Could Be the Hottest Stock of the Summer Analysts Keep Boosting Taiwan Semiconductor Stock—Here's Why Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
